Evaluation of clinical staging in chronic lymphocytic leukemia-population-based study

被引:15
作者
Apelgren, Peter [1 ]
Hasselblom, Sverker [1 ]
Werlenius, Olle [1 ]
Nilsson-Ehle, Herman [1 ]
Andersson, Per-Ola [1 ]
机构
[1] Sahlgrens Univ Hosp, Dept Internal Med, Sect Haematol & Coagulat, SE-41345 Gothenburg, Sweden
关键词
CLL; clinical staging; Binet; Rai; prognosis; population-based;
D O I
10.1080/10428190600881322
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Rai and Binet staging systems are currently being challenged by the development of new biological methods to characterize the prognosis and management of chronic lymphocytic leukemia (CLL). To evaluate these two systems in recently diagnosed CLL patients, we performed a retrospective population-based study including 344 patients in western Sweden diagnosed between 1995 and 2000. Binet stage A patients had longer median overall survival ( OS) ( 100 months) than stage B ( 55 months; P<0.001) and C patients ( 45 months; P<0.0005). Median OS for stage B and C could not be separated ( P = 0.94). When transferring Rai stages into three groups, a similar pattern was found. Overall response differed only between Binet A and C patients and there was no difference regarding time to next treatment between any of the Binet stages. Finally, in both systems, low stage patients had inferior survival compared to age- and sex-matched controls. Our data emphasize the need for a new risk stratification system for CLL patients.
引用
收藏
页码:2505 / 2516
页数:12
相关论文
共 41 条
[1]  
[Anonymous], 1990, Blood, V75, P1422
[2]  
[Anonymous], 1990, Blood, V75, P1414
[3]   Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia [J].
Binet, JL ;
Caligaris-Cappio, F ;
Catovsky, D ;
Cheson, B ;
Davis, T ;
Dighiero, G ;
Döhner, H ;
Hallek, M ;
Hillmen, P ;
Keating, M ;
Montserrat, E ;
Kipps, TJ ;
Rai, K .
BLOOD, 2006, 107 (03) :859-861
[4]  
BINET JL, 1990, BRIT J HAEMATOL, V76, P45
[5]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[6]  
2-V
[7]   Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy [J].
Byrd, JC ;
Gribben, JG ;
Peterson, BL ;
Grever, MR ;
Lozanski, G ;
Lucas, DM ;
Lampson, B ;
Larson, RA ;
Caligiuri, MA ;
Heerema, NA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :437-443
[8]   INCIDENCE OF CHRONIC LYMPHOCYTIC-LEUKEMIA IN OLMSTED COUNTY, MINNESOTA, 1935 THROUGH 1989, WITH EMPHASIS ON CHANGES IN INITIAL-STAGE AT DIAGNOSIS [J].
CALL, TG ;
PHYLIKY, RL ;
NOEL, P ;
HABERMANN, TM ;
BEARD, CM ;
OFALLON, WM ;
KURLAND, LT .
MAYO CLINIC PROCEEDINGS, 1994, 69 (04) :323-328
[9]   PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC-LEUKEMIA - THE IMPORTANCE OF AGE, SEX AND RESPONSE TO TREATMENT IN SURVIVAL - A REPORT FROM THE MRC CLL 1 TRIAL [J].
CATOVSKY, D ;
FOOKS, J ;
RICHARDS, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (02) :141-149
[10]  
Catovsky D, 2005, BLOOD, V106, p212A